CurrentUnitedHealthcarePolicy CS069NJ.R

Light and Laser Therapy Nj Cs

UnitedHealthcare Community Plan medical policy for New Jersey that defines medical necessity and noncoverage positions for various light and laser therapies (e.g., pulsed dye laser, fractional ablative laser fenestration, laser hair removal) and lists applicable procedure and diagnosis codes, documentation requirements, and clinical evidence summaries for indications including port-wine stains, hemangiomas, hypertrophic burn scars, pilonidal sinus disease, acne, onychomycosis, rosacea, and rhinophyma.

Policy Summary

PayerUnitedHealthcare

PolicyLight and Laser Therapy Nj Cs

Policy CodePolicy CS069NJ.R

Change TypeRevised/Added references and documentation language

Effective DateFeb 1, 2026

Next Review Date

Key ActionEnsure the patient medical record contains history, physical exam, and diagnostic test results that fully support medical necessity and be prepared to provide documentation on request.

SourceLink

POLICY UPDATE CHANGES

Updated list of examples of unproven and not medically necessary light and laser therapies; removed 'excimer'.

Added reference link to the Medical Policy titled 'Outpatient Surgical Procedures - Site of Service (for New Jersey Only)'.

Added language clarifying documentation used for reviews including statements that coverage is governed by federal/state/contractual requirements and that documentation does not guarantee coverage.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect current information.

3Proven & medically necessary indications

4Unproven / not medically necessary

~20

Cited studies/reviews

heterogeneousEvidence consistency

FDA 510(k)Device clearance status mentioned

Coverage Summary

This New Jersey–specific medical policy addresses clinical indications, coding, and documentation requirements for a spectrum of light and laser therapies. It affirms pulsed dye laser (PDL) as the established standard for port‑wine stains and cutaneous hemangiomas, supports fractional ablative laser fenestration (e.g., CO2, Er:YAG) for hypertrophic burn scars when functional impairment persists and at least one conventional therapy has failed, and recognizes laser hair removal/destruction (LHR/LHD) as proven when used as an adjunct (or alternative) to surgery for control of hair regrowth in pilonidal sinus disease. The policy lists applicable procedure and diagnosis codes and specifies required medical record documentation to support medical necessity.

Coverage determination and applicability are limited to the State of New Jersey. Benefit coverage may still be governed by applicable federal, state, or contractual requirements which can supersede this policy; medical record documentation may be requested to verify clinical criteria but does not guarantee coverage.

Surface select threshold and policy metadata

Policy NumberCS069NJ.R

Effective DateFebruary 1, 2026

Scope SummaryUnitedHealthcare Community Plan medical policy for New Jersey defining medical necessity and noncoverage positions for various light and laser therapies and listing applicable procedure and diagnosis codes, documentation requirements, and evidence summaries for multiple indications

Coverage StanceMixed — some indications proven & medically necessary (e.g., PDL for port-wine stains and hemangiomas; LHR for pilonidal sinus disease; fractional ablative laser fenestration for hypertrophic burn scars when criteria met); other indications unproven/not medically necessary (e.g., acne, onychomycosis, rosacea, rhinophyma)

Prior conventional therapy requiredFor hypertrophic burn scars: at least one conventional treatment tried and failed (e.g., hypoallergenic paper tape, pressure garments, or silicone kits with gel/sheeting)

Medical Necessity Criteria

Proven and Medically Necessary

Covered when ALL of the following are met:

ALL of the following

Pulsed dye laser therapy is being used to treat a port-wine stain (PWS).
PDL includes cryogen spray-cooled PDL (CPDL) where applicable.
Pulsed dye laser therapy is being used to treat cutaneous hemangioma/hemangiomata (including infantile hemangiomas).
Treatment goals include removal, lightening, reduction in size, regression of lesion, or relief of symptoms/complications.

General evidence-based coverage considerations for laser/light therapy

Therapies must have sufficient published evidence demonstrating clinically meaningful improvement in health outcomes relevant to the indication (e.g., functional improvement, lesion regression, symptom relief).

Coverage Rationale & Evidence Summary

The policy bases its recommendations on guideline statements and a heterogeneous body of evidence: NICE issued a conditional 'consider' recommendation for PDT in adults ≥18 with moderate–severe acne when other treatments are ineffective, not tolerated, or contraindicated, while the AAD (2024) concluded evidence is insufficient to support routine use of laser and light devices for acne. Systematic reviews and HTAs rate evidence for fractional CO2/ablative lasers in hypertrophic burn scars as generally low to very low quality but suggest possible functional and scar‑severity improvements; Hayes and Cochrane reviews note safety but emphasize limited certainty and heterogeneity.

FDA device clearances (510(k)) for multiple phototherapy, PDT, and laser devices are cited for informational purposes only and do not by themselves establish coverage. For acne, onychomycosis, rosacea, and rhinophyma the evidence is mixed and limited by small, single‑center trials, variable protocols, short follow‑up, and inconsistent endpoints: PDT and visible light show promise for acne but trial quality and heterogeneity limit firm conclusions; onychomycosis trials suggest combination laser + topical antifungal may outperform topical therapy alone but monotherapy evidence is insufficient; rosacea and rhinophyma have small studies or case series suggesting potential benefit (e.g., IPL, PDL, CO2/Er:YAG) but evidence is low quality and not definitive.

Evidence Item	Takeaway
Hashemi et al. 2024
Systematic review of 33 pediatric studies (7725 patients) showing PDL (595 nm) has high >50% clearance rates in many studies and very low rates of permanent adverse effects — supports PDL as gold-standard for PWS/hemangiomas.
Shi et al. 2023
Large systematic review (65 studies, 6537 patients) reporting frequent acute reactions (purpura, edema) but low long-term complications with PDL — supports safety profile and common transient AEs.
Muscat et al. 2024
Meta-analysis of 3 RCTs found significantly lower pilonidal disease recurrence with laser hair removal (OR ~0.319) — evidence supports LHR/LHD as effective adjunct to reduce recurrence.
Minneci et al. 2024
Large RCT (n=302) showing adjunctive laser epilation reduced 1-year recurrence from 33.2% to 23.2% — randomized evidence supporting benefit of LE plus standard care.
Hayes HTA (2023–2024)
Health technology assessment rates fractional laser treatment evidence as low quality but suggests CO2 FLT may be reasonably safe and may improve function for hypertrophic/traumatic scars — supports conditional coverage when criteria met.
Cochrane review (2022)
Cochrane synthesis of 15 RCTs (604 participants) found very low‑certainty evidence for fractional CO2 lasers versus no treatment — indicates limited high‑quality evidence and need for more RCTs despite positive findings in some studies.
Betar et al. 2025 / Bergus et al. 2024
Cohort and pediatric series report meaningful improvements in scar thickness, POSAS/VSS scores and function with AF-CO2/fractional CO2 lasers, with low rates of infection/delayed healing — clinical series align with HTA and meta-analyses.
Onychomycosis meta-analyses (Zhang 2022, Han 2021)
Meta-analyses suggest laser combined with topical antifungals yields better mycological/clinical outcomes than topical alone, but overall evidence quality is variable — does not support laser monotherapy.
Rosacea/rhinophyma systematic reviews and small trials
Small RCTs and case series (IPL, PDL, CO2, KTP) show possible benefit but heterogeneous and low-quality data — evidence insufficient for routine coverage outside specific scenarios.

Definitions

Key terms used in the policy: Light therapy — exposure to nonionizing radiation for therapeutic benefit (includes phototherapy, IPL, PDT). Photodynamic therapy (PDT) — visible light plus a topical photosensitizer (e.g., ALA, MAL). Pulsed dye laser (PDL) — commonly 595 nm wavelength for cutaneous vascular lesions. Ablative fractional CO2 laser (AFCO2L) — a fractional ablative carbon dioxide laser used for scar fenestration. POSAS — Patient and Observer Scar Assessment Scale. VSS/mVSS — (modified) Vancouver Scar Scale. LHR / LHD — laser hair removal / laser hair destruction. IPL — intense pulsed light. KTP — potassium titanyl phosphate laser (≈532 nm). Er:YAG — Erbium:YAG laser (≈2940 nm).

Coding

Covered / Reference CPT codes for Cutaneous Vascular LesionsCPTCovered

17106	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); less than 10 sq cm
17107	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); 10.0 to 50.0 sq cm
17108	Destruction of cutaneous vascular proliferative lesions (e.g., laser technique); over 50.0 sq cm

Covered / Fractional ablative laser fenestration codes (not on NJ Medicaid fee schedule flagged with asterisk)CPTCovered

0479T	Fractional ablative laser fenestration of burn and traumatic scars for functional improvement; first 100 cm2 or part thereof, or 1% of body surface area of infants and children (* may not be on NJ Medicaid Fee Schedule)
0480T	Fractional ablative laser fenestration... each additional 100 cm2, or each additional 1% BSA of infants and children (add-on) (* may not be on NJ Medicaid Fee Schedule)

Unlisted procedure codes referencedCPT

17999

Unlisted procedure, skin, mucous membrane, and subcutaneous tissue (used for laser hair removal and other unlisted skin procedures)

Diagnosis codes - Cutaneous vascular lesions / hemangiomasICD-10

D18.00	Hemangioma unspecified site
D18.01	Hemangioma of skin and subcutaneous tissue
I78.0	Hereditary hemorrhagic telangiectasia
I78.1	Nevus, non-neoplastic
Q82.5	Congenital non-neoplastic nevus
Q85.89	Other phakomatoses, not elsewhere classified

Diagnosis codes - Hypertrophic burn scarsICD-10

L90.5	Scar conditions and fibrosis of skin
L91.0	Hypertrophic scar

Diagnosis codes - Pilonidal diseaseICD-10

L05.01	Pilonidal cyst with abscess
L05.02	Pilonidal sinus with abscess
L05.91	Pilonidal cyst without abscess
L05.92	Pilonidal sinus without abscess

FDA device/product references (informational)mixed

GEX/FTC	FDA product codes referenced for phototherapy/PDL/laser devices (informational links provided)
MVF	FDA product code referenced for photodynamic therapy devices (informational)

Covered / Reference CPT codes - PDL and related device classification (informational)mixedCovered

PDL	Pulsed dye laser noted as gold standard for port-wine stains; device class II; FDA 510(k) info product code GEX (informational)

State-note for *0479T/*0480TModifierCovered

*	Codes labeled with an asterisk are not on the State of New Jersey Medicaid Fee Schedule and may not be covered by NJ Medicaid

Provider Actions & Documentation

Documentation Required

Medical record documentation required

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. Documentation should include, but is not limited to, relevant medical history, physical examination findings, results of pertinent diagnostic tests or procedures, and rationale for the selected light or laser therapy. Records must be legible, maintained in the patient's medical record, and made available upon request. Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage but does not guarantee coverage of the services requested.

Include relevant history, exam findings, and diagnostic test results.
Document prior conservative or alternative treatments tried and the clinical response to those treatments.
Describe the specific indication for the proposed procedure and expected functional or clinical benefit.
For procedures addressing functional impairment (e.g., hypertrophic burn scars), document how the scar limits function (range of motion, pain, activities of daily living) and why laser therapy is expected to improve function.

Not Covered / Experimental

Unproven and Not Medically Necessary (cross-reference)

Not covered due to insufficient evidence of efficacy:

ANY of the following

Acne vulgaris
Listed as unproven/not medically necessary due to insufficient evidence
Onychomycosis
Listed as unproven/not medically necessary due to insufficient evidence
Rhinophyma
Listed as unproven/not medically necessary due to insufficient evidence
Rosacea
Listed as unproven/not medically necessary due to insufficient evidence

Medicare / External Guideline Determinations

Source	Type	Note
NICE guidance referenced
NCD
NICE made a 'consider' recommendation for PDT in adults (>=18) with moderate‑to‑severe acne if other treatments ineffective, not tolerated, or contraindicated — referenced in policy.

Revision History

02/01/2026revised/added

Updated list of examples of unproven and not medically necessary light and laser therapies; removed 'excimer'.

02/01/2026added

Added reference link to the Medical Policy titled 'Outpatient Surgical Procedures - Site of Service (for New Jersey Only)'.

02/01/2026added

Added language clarifying documentation used for reviews including statements that coverage is governed by federal/state/contractual requirements and that documentation does not guarantee coverage; patient medical record must contain documentation that fully supports medical necessity and be made available upon request.

Policy Summary

PayerUnitedHealthcare

PolicyLight and Laser Therapy Nj Cs

Policy CodePolicy CS069NJ.R

Change TypeRevised/Added references and documentation language

Effective DateFeb 1, 2026

Next Review Date

Key ActionEnsure the patient medical record contains history, physical exam, and diagnostic test results that fully support medical necessity and be prepared to provide documentation on request.

SourceLink

On This Page

Evidence should include study design, population, magnitude of benefit, durability, and safety profile.

Use of laser or light-based modalities for cosmetic indications without objective functional or clinical benefit is not considered medically necessary.

Documentation should clearly describe the medical necessity and expected clinical benefit.

Prior to coverage, medical records must document diagnosis, prior conservative therapies tried (when applicable), reason for device selection, planned treatment parameters, and measurable treatment goals/outcomes.

Coverage Rationale / Evidence Summary (Rosacea & Rhinophyma)

For rosacea, available evidence is insufficient to establish consistent, durable clinical benefit for laser and IPL therapies across the range of rosacea signs (e.g., erythema, telangiectasia, papules/pustules).
Published studies vary in methodology, outcomes measured, and follow-up duration; long-term benefit and comparative effectiveness versus medical therapy remain uncertain.
For rhinophyma, laser surgery and other ablative techniques have been reported in case series and nonrandomized studies to reduce bulk and contour deformity, but high-quality comparative evidence demonstrating superior outcomes or durability compared with established surgical techniques is limited.
Because evidence is limited and heterogeneous, rhinophyma treatment with laser is considered unproven/not medically necessary unless supported by documentation that alternative standard surgical approaches are unsuitable and that expected functional or significant symptomatic benefit outweighs risks.

Laser Hair Removal - Pilonidal Sinus Disease

Laser hair removal is proven and medically necessary when:

ALL of the following

Diagnosis of pilonidal sinus disease (e.g., pilonidal cyst or pilonidal sinus).
Relevant ICD-10 diagnosis codes should be documented in the medical record.
Laser hair removal is being used as an adjunct to, or alternative to, surgery for control of hair regrowth to reduce recurrence or recurrent infection.
Documentation must indicate prior or planned surgical management and rationale for adjunctive/alternative LHR; clinical records should document hair-related contribution to disease and expected benefit.
General evidence-based coverage considerations: noninvasive LHR devices used for pilonidal disease should have published evidence demonstrating reduction in recurrence or need for repeat surgery compared with standard care.
Treatment parameters, number of sessions, and expected timeline for response should be provided in the record.

Operational notes

LHR should be delivered by appropriately trained providers with documentation of device type and treatment parameters.
Billing should use appropriate CPT/HCPCS or unlisted procedure codes with supporting operative notes; 17999 may be used when no specific code exists.
Medical records must document prior therapies and the clinical rationale for choosing laser hair removal, and include follow-up demonstrating effectiveness or need for continued therapy.
Coverage decisions may require demonstration of recurrence reduction or avoidance of additional surgical procedures.

General evidence-based coverage considerations for laser/light therapy

Indications supported by evidence demonstrating meaningful clinical improvement (e.g., reduced recurrence, improved function) are considered medically necessary.
Indication-specific evidence strength and quality inform coverage determinations.

Fractional Ablative Laser Fenestration - Hypertrophic Burn Scars

Covered when ALL of the following are met:

ALL of the following

The hypertrophic burn scar is causing functional impairment (for example, limiting range of motion) and the procedure can be reasonably expected to improve the functional impairment.
Objective documentation of functional limitation (e.g., range-of-motion measurements, impairment assessments) must be in the medical record.
The individual has tried and failed at least one conventional treatment (e.g., hypoallergenic paper tape, pressure garments, or silicone kits with gel/sheeting).>= 1 modality tried and failed
Documentation should include type(s) of conventional therapy used, duration, adherence, and the reason(s) therapy was considered unsuccessful.
Procedure example: Fractional ablative laser fenestration (e.g., CO2, Er:YAG) of hypertrophic burn scars performed with the intent of functional improvement.
CPT-like coding guidance: *0479T for the first 100 cm2 or part thereof (or 1% BSA in infants/children) and *0480T for each additional 100 cm2 (or additional 1% BSA). If these codes are not available on the payer schedule, unlisted procedure code 17999 may be reported with operative documentation specifying technique and surface area treated.
Sizing guidance: report surface area treated per billing interval; when using *0479T/*0480T, follow the per-100 cm2 (or pediatric 1% BSA) increments described above.
Codes marked with an asterisk may not be on the NJ Medicaid Fee Schedule; verify state-specific coverage and fee schedule applicability.

General evidence-based coverage considerations for laser/light therapy

Evidence supports fractional ablative laser fenestration for improving scar thickness, pliability, pain, and joint movement in selected patients with hypertrophic burn scars when conventional measures have failed.
Treatment should be targeted to achieve functional gains; cosmetic-only indications without functional impairment are not covered.

Unproven and Not Medically Necessary

Not covered due to insufficient evidence of efficacy:

ANY of the following

Acne vulgaris - light and laser therapy is considered unproven/not medically necessary due to insufficient consistent evidence of durable clinical benefit.
Onychomycosis - laser treatment approaches are considered unproven/not medically necessary given mixed evidence and lack of consistent superiority to standard antifungal therapy.
Rhinophyma - laser and light therapies are considered unproven/not medically necessary for routine treatment; evidence is limited and heterogeneous; surgical techniques have more established outcomes.
Rosacea - laser and IPL therapies are considered unproven/not medically necessary for routine management of rosacea signs and symptoms due to inconsistent evidence and uncertain long-term benefit.

Coverage Rationale / Evidence Summary (Rosacea & Rhinophyma)

Rosacea: studies of laser and IPL report variable improvements in erythema and telangiectasia but are limited by small sample sizes, heterogeneous endpoints, and short follow-up; therefore, these therapies remain unproven for routine rosacea management unless documented as medically necessary for refractory, objectively measured disease after standard medical therapy.
Rhinophyma: while case series report contour improvement after ablative laser or surgical modalities, high-quality comparative evidence is lacking; rhinophyma treatment with laser is not routinely covered unless documentation shows standard surgical techniques are unsuitable and significant functional or symptomatic benefit is expected.

General evidence-based coverage considerations for laser/light therapy

Treatments listed as unproven/not medically necessary lack sufficient high-quality evidence demonstrating consistent, meaningful clinical outcomes. Coverage is not provided for investigational or cosmetic uses absent compelling documentation of medical necessity.

Billing Rule

Coding clarification for warts (codes 17106/17107/17108)

Viral or plantar warts are not vascular proliferative lesions; laser treatment for warts should not be reported with CPT codes 17106, 17107, or 17108. Use appropriate wart-related procedure codes instead of the cutaneous vascular lesion codes.

Affected codes: 17106, 17107, 17108

Prior Authorization

State-specific coverage applicability

The fractional ablative laser fenestration codes 0479T and 0480T are specific to New Jersey policy application. Note that codes marked with an asterisk may not be on the State of New Jersey Medicaid Fee Schedule and therefore may not be covered by the State Medicaid Program; confirm fee-schedule applicability prior to billing.

Affected codes: 0479T, 0480T
Note: Codes with an asterisk (*) are not on the NJ Medicaid Fee Schedule and may not be covered.

Documentation Required

Document indication and prior treatments

When considering photodynamic therapy (PDT) for acne, document the specific indication, prior treatments attempted, and clinical rationale. For onychomycosis, if laser therapy is being used as adjunctive or alternative treatment, document prior use and response to topical and/or systemic antifungal agents and why laser therapy is being considered.

Document indication and prior medical therapies for acne when proposing PDT.
For onychomycosis, document prior topical and/or systemic antifungal treatments and treatment response before considering laser therapy as adjunctive or alternative care.

Prior Authorization

Prior authorization may be required for device-based dermatologic procedures

Prior authorization may be required for device-based dermatologic procedures. Providers should verify prior authorization requirements with the member's plan and submit supporting documentation to demonstrate medical necessity if requested. Supporting documentation may include clinical notes, imaging or diagnostic test results, previous treatment records showing failure of conservative therapies, and a description of functional impairment when applicable.

Prior authorization may be required — verify with member's plan.
Include clinical notes, diagnostic results, prior treatment records, and documentation of functional impairment as applicable.

Documentation Required

Follow federal/state/contractual coverage requirements

Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws; these requirements may supersede policy statements. Providers must follow the member's contractual, federal, and state coverage rules and supply documentation as required to demonstrate eligibility and medical necessity.

Follow federal, state, and contractual coverage requirements; they may supersede policy provisions.
Medical records documentation may be requested to assess whether the member meets clinical criteria for coverage.

Cross-reference note: These indications are considered not covered due to insufficient evidence of efficacy per policy Coverage Rationale and evidence summaries

Repeat/cross-reference of Unproven and Not Medically Necessary criteria

Some studies indicate that combining laser treatments with topical antifungals for onychomycosis yields better mycological and clinical outcomes than topical therapy alone, but results are variable and trial quality is inconsistent. The policy therefore does not endorse laser monotherapy for onychomycosis and notes that combination approaches have mixed evidence and should be documented as adjunctive when used.

02/01/2026revisedLatest

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect current information; archived previous policy version CS069NJ.Q.